Optimization of MrgX1 allosteric agonists as potential therapies for chronic pain
Optimization of MrgX1 allosteric agonists as potential therapies for chronic pain
批准号:
9903279
负责人:
Corey R. Hopkins
金额:
$39.25万
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-09-15 至 2022-02-28
关键词:
Adverse effectsAffectiveAfferent NeuronsAgonistAnalgesicsBackBindingBinding ProteinsBiological AssayBrainCaliberCellular AssayCharacteristicsClinicalDataDevelopmentDoseDose-LimitingDrug KineticsEquilibriumFamilyFundingFutureG-Protein-Coupled ReceptorsGoalsGrantHealthHomologous GeneHumanIn VitroInterventionLeadLigationMeasuresMedicineModelingMusNeuraxisNeuronsNociceptorsOpioidOralOrphanPainPathway interactionsPenetrationPermeabilityPersistent painPharmaceutical ChemistryPharmaceutical PreparationsPharmacologyPhasePlasmaPlasma ProteinsPlayPositioning AttributePropertyResearchRiskRoleSignal TransductionSkinSolubilitySpinal GangliaSpinal nerve structureTestingToxicologyVisceraWorkaddictionanalogchemical synthesischronic constriction injurychronic painconditioned place preferencedesignexperiencehealth economicsimprovedin vivoin vivo evaluationlead optimizationmeetingsmembermouse modelnovelpain modelpharmacokinetics and pharmacodynamicspre-clinicalprogramsreceptorscaffoldside effectspontaneous paintooltransmission process
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Chronic pain is a major health and economic problem worldwide. Because the major analgesics (e.g., opioids)
bind to receptors that are widely expressed throughout the central nervous system (CNS), dose-limiting
adverse effects and significant risk of addiction and abuse present substantial barriers to their clinical use. Pain
sensing neurons (a.k.a nociceptors) in dorsal root ganglion (DRG) play essential role in pain transmission by
detecting painful signals in the periphery such as skin and viscera. Therefore, targeting molecules specifically
expressed in nociceptors may offer an opportunity for pain-selective pharmacologic interventions. Our previous
data have shown that Mrgs including mouse MrgC11 and human MrgX1 are specifically expressed in
nociceptors in DRG and constitute an endogenous anti-pain pathway. Funded R03 grant allowed us to identify
selective and potent MrgX1 allosteric agonists. Preliminary data showed that two allosteric agonists inhibited
persistent pain in humanized MrgX1 mice. MrgX1 allosteric agonists may potentially become novel anti-chronic
pain drugs with limited CNS-related side effects. In this proposal, we will improve and optimize MrgX1 allosteric
agonists and test their analgesic efficacy in mice. Highly selective agonists, and for the purpose of this
proposal, allosteric agonists, are needed in order to better understand the respective role of MrgX1 in these
studies of chronic pain. We have recently discovered a novel class of allosteric agonists with potency on
MrgX1 and selectivity against MrgX2. These selective allosteric agonists offer a unique opportunity to test the
hypothesis presented in this proposal. In order to develop first-in-class, potent, selective and CNS penetrant
MrgX1 allosteric agonists, we will optimize our lead scaffold such that the tool compound will possess the
appropriate properties, a balance of potency, selectivity and DMPK. We will utilize an iterative medicinal
chemistry approach which will enable all of the attributes to be evaluated in parallel. Once the tool
compound(s) have been determined, we will then test these compounds in the humanized MrgX1 mouse
model.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Discovery and characterization of selective GIRK1/2 activators and their evaluation in preclinical models of pain
-
批准号:10590728
-
项目类别:
-
资助金额:$52.87万
-
财政年份:2022
-
负责人:Corey R. Hopkins
-
依托单位:
Discovery and characterization of selective D4R antagonists and their evaluation in preclinical models of PD-LIDs
-
批准号:10434146
-
项目类别:
-
资助金额:$39.53万
-
财政年份:2021
-
负责人:Corey R. Hopkins
-
依托单位:
Discovery and characterization of selective D4R antagonists and their evaluation in preclinical models of PD-LIDs
-
批准号:10314276
-
项目类别:
-
资助金额:$38.05万
-
财政年份:2021
-
负责人:Corey R. Hopkins
-
依托单位:
Discovery and characterization of selective D4R antagonists and their evaluation in preclinical models of PD-LIDs
-
批准号:10642849
-
项目类别:
-
资助金额:$56.0万
-
财政年份:2021
-
负责人:Corey R. Hopkins
-
依托单位:
Optimization of MrgX1 allosteric agonists as potential therapies for chronic pain
-
批准号:10112868
-
项目类别:
-
资助金额:$39.25万
-
财政年份:2017
-
负责人:Corey R. Hopkins
-
依托单位:
Optimization of novel inhibitors of TRPC5 as anti-proteinuric therapeutics
-
批准号:9335339
-
项目类别:
-
资助金额:$31.71万
-
财政年份:2016
-
负责人:Corey R. Hopkins
-
依托单位:
Development of an In Vivo, Brain-penetrant GIRK1/2 Potassium Channel Activator
-
批准号:8941166
-
项目类别:
-
资助金额:$58.33万
-
财政年份:2015
-
负责人:Corey R. Hopkins
-
依托单位:
Development of an In Vivo, Brain-penetrant GIRK1/2 Potassium Channel Activator
-
批准号:9090183
-
项目类别:
-
资助金额:$51.21万
-
财政年份:2015
-
负责人:Corey R. Hopkins
-
依托单位:
Optimization of novel inhibitors of TRPC5 as anti-proteinuric therapeutics
-
批准号:8800654
-
项目类别:
-
资助金额:$36.81万
-
财政年份:2014
-
负责人:Corey R. Hopkins
-
依托单位:
Optimization of novel inhibitors of TRPC5 as anti-proteinuric therapeutics
-
批准号:8926413
-
项目类别:
-
资助金额:$35.52万
-
财政年份:2014
-
负责人:Corey R. Hopkins
-
依托单位:
海外基金